189 related articles for article (PubMed ID: 35672381)
1. Overexpression of alanine-glyoxylate aminotransferase 2 protects from asymmetric dimethylarginine-induced endothelial dysfunction and aortic remodeling.
Rodionov RN; Jarzebska N; Burdin D; Todorov V; Martens-Lobenhoffer J; Hofmann A; Kolouschek A; Cordasic N; Jacobi J; Rubets E; Morawietz H; O'Sullivan JF; Markov AG; Bornstein SR; Hilgers K; Maas R; Pfluecke C; Chen Y; Bode-Böger SM; Hugo CPM; Hohenstein B; Weiss N
Sci Rep; 2022 Jun; 12(1):9381. PubMed ID: 35672381
[TBL] [Abstract][Full Text] [Related]
2. Human alanine-glyoxylate aminotransferase 2 lowers asymmetric dimethylarginine and protects from inhibition of nitric oxide production.
Rodionov RN; Murry DJ; Vaulman SF; Stevens JW; Lentz SR
J Biol Chem; 2010 Feb; 285(8):5385-91. PubMed ID: 20018850
[TBL] [Abstract][Full Text] [Related]
3. AGXT2 and DDAH-1 genetic variants are highly correlated with serum ADMA and SDMA levels and with incidence of coronary artery disease in Egyptians.
Amir M; Hassanein SI; Abdel Rahman MF; Gad MZ
Mol Biol Rep; 2018 Dec; 45(6):2411-2419. PubMed ID: 30284143
[TBL] [Abstract][Full Text] [Related]
4. Role of alanine:glyoxylate aminotransferase 2 in metabolism of asymmetric dimethylarginine in the settings of asymmetric dimethylarginine overload and bilateral nephrectomy.
Rodionov RN; Martens-Lobenhoffer J; Brilloff S; Hohenstein B; Jarzebska N; Jabs N; Kittel A; Maas R; Weiss N; Bode-Böger SM
Nephrol Dial Transplant; 2014 Nov; 29(11):2035-42. PubMed ID: 25002409
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of dimethylarginine dimethylaminohydrolase inhibits asymmetric dimethylarginine-induced endothelial dysfunction in the cerebral circulation.
Dayoub H; Rodionov RN; Lynch C; Cooke JP; Arning E; Bottiglieri T; Lentz SR; Faraci FM
Stroke; 2008 Jan; 39(1):180-4. PubMed ID: 18063827
[TBL] [Abstract][Full Text] [Related]
6. Effects of AGXT2 variants on blood pressure and blood sugar among 750 older Japanese subjects recruited by the complete enumeration survey method.
Yoshino Y; Kumon H; Mori T; Yoshida T; Tachibana A; Shimizu H; Iga JI; Ueno SI
BMC Genomics; 2021 Apr; 22(1):287. PubMed ID: 33879046
[TBL] [Abstract][Full Text] [Related]
7. Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage.
Tomlinson JA; Caplin B; Boruc O; Bruce-Cobbold C; Cutillas P; Dormann D; Faull P; Grossman RC; Khadayate S; Mas VR; Nitsch DD; Wang Z; Norman JT; Wilcox CS; Wheeler DC; Leiper J
J Am Soc Nephrol; 2015 Dec; 26(12):3045-59. PubMed ID: 25855779
[TBL] [Abstract][Full Text] [Related]
8. In vivo evidence that Agxt2 can regulate plasma levels of dimethylarginines in mice.
Kittel A; Maas R; König J; Mieth M; Weiss N; Jarzebska N; Hohenstein B; Martens-Lobenhoffer J; Bode-Böger SM; Rodionov RN
Biochem Biophys Res Commun; 2013 Jan; 430(1):84-9. PubMed ID: 23154179
[TBL] [Abstract][Full Text] [Related]
9. Kidney and liver are the main organs of expression of a key metabolic enzyme alanine:glyoxylate aminotransferase 2 in humans.
Jarzebska N; Georgi S; Jabs N; Brilloff S; Maas R; Rodionov RN; Zietz C; Montresor S; Hohenstein B; Weiss N
Atheroscler Suppl; 2019 Dec; 40():106-112. PubMed ID: 31818439
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of dimethylarginine dimethylaminohydrolase 1 protects from angiotensin II-induced cardiac hypertrophy and vascular remodeling.
Kopaliani I; Jarzebska N; Billoff S; Kolouschek A; Martens-Lobenhoffer J; Bornstein SR; Bode-Böger SM; Ragavan VN; Weiss N; Mangoni AA; Deussen A; Rodionov RN
Am J Physiol Heart Circ Physiol; 2021 Nov; 321(5):H825-H838. PubMed ID: 34533401
[TBL] [Abstract][Full Text] [Related]
11. AGXT2: An unnegligible aminotransferase in cardiovascular and urinary systems.
Hu XL; Li MP; Song PY; Tang J; Chen XP
J Mol Cell Cardiol; 2017 Dec; 113():33-38. PubMed ID: 28970090
[TBL] [Abstract][Full Text] [Related]
12. Effect of lowering asymmetric dimethylarginine (ADMA) on vascular pathology in atherosclerotic ApoE-deficient mice with reduced renal mass.
Jacobi J; Maas R; Arend M; Cordasic N; Hilgers KF
Int J Mol Sci; 2014 Mar; 15(4):5522-35. PubMed ID: 24690995
[TBL] [Abstract][Full Text] [Related]
13. The Second Life of Methylarginines as Cardiovascular Targets.
Jarzebska N; Mangoni AA; Martens-Lobenhoffer J; Bode-Böger SM; Rodionov RN
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31533264
[TBL] [Abstract][Full Text] [Related]
14. Diabetes-linked transcription factor HNF4α regulates metabolism of endogenous methylarginines and β-aminoisobutyric acid by controlling expression of alanine-glyoxylate aminotransferase 2.
Burdin DV; Kolobov AA; Brocker C; Soshnev AA; Samusik N; Demyanov AV; Brilloff S; Jarzebska N; Martens-Lobenhoffer J; Mieth M; Maas R; Bornstein SR; Bode-Böger SM; Gonzalez F; Weiss N; Rodionov RN
Sci Rep; 2016 Oct; 6():35503. PubMed ID: 27752141
[TBL] [Abstract][Full Text] [Related]
15. Alanine-glyoxylate aminotransferase 2 (AGXT2) polymorphisms have considerable impact on methylarginine and β-aminoisobutyrate metabolism in healthy volunteers.
Kittel A; Müller F; König J; Mieth M; Sticht H; Zolk O; Kralj A; Heinrich MR; Fromm MF; Maas R
PLoS One; 2014; 9(2):e88544. PubMed ID: 24586340
[TBL] [Abstract][Full Text] [Related]
16. ADMA reduction does not protect mice with streptozotocin-induced diabetes mellitus from development of diabetic nephropathy.
Rodionov RN; Heinrich A; Brilloff S; Jarzebska N; Martens-Lobenhoffer J; Bode-Böger SM; Todorov VT; Hugo CPM; Weiss N; Hohenstein B
Atheroscler Suppl; 2017 Nov; 30():319-325. PubMed ID: 29096857
[TBL] [Abstract][Full Text] [Related]
17. Adenoviral-mediated overexpression of DDAH improves vascular tone regulation.
Torondel B; Nandi M; Kelly P; Wojciak-Stothard B; Fleming I; Leiper J
Vasc Med; 2010 Jun; 15(3):205-13. PubMed ID: 20219849
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide association study of L-arginine and dimethylarginines reveals novel metabolic pathway for symmetric dimethylarginine.
Lüneburg N; Lieb W; Zeller T; Chen MH; Maas R; Carter AM; Xanthakis V; Glazer NL; Schwedhelm E; Seshadri S; Ikram MA; Longstreth WT; Fornage M; König IR; Loley C; Ojeda FM; Schillert A; Wang TJ; Sticht H; Kittel A; König J; Benjamin EJ; Sullivan LM; Bernges I; Anderssohn M; Ziegler A; Gieger C; Illig T; Meisinger C; Wichmann HE; Wild PS; Schunkert H; Psaty BM; Wiggins KL; Heckbert SR; Smith N; Lackner K; Lunetta KL; Blankenberg S; Erdmann J; Munzel T; Grant PJ; Vasan RS; Böger RH
Circ Cardiovasc Genet; 2014 Dec; 7(6):864-72. PubMed ID: 25245031
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of dimethylarginine dimethylaminohydrolase protects against cerebral vascular effects of hyperhomocysteinemia.
Rodionov RN; Dayoub H; Lynch CM; Wilson KM; Stevens JW; Murry DJ; Kimoto M; Arning E; Bottiglieri T; Cooke JP; Baumbach GL; Faraci FM; Lentz SR
Circ Res; 2010 Feb; 106(3):551-8. PubMed ID: 20019334
[TBL] [Abstract][Full Text] [Related]
20. Genetic variation in the dimethylarginine dimethylaminohydrolase 1 gene (DDAH1) is related to asymmetric dimethylarginine (ADMA) levels, but not to endothelium-dependent vasodilation.
Lind L; Ingelsson E; Kumar J; Syvänen AC; Axelsson T; Teerlink T
Vasc Med; 2013 Aug; 18(4):192-9. PubMed ID: 23892448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
